Xerthra
Xerthra iPRF
Injectable platelet rich fibrin
Derived from Xerthra PRP technology, iPRF creates a stable fibrin network that concentrates platelets and other blood components, gradually releasing growth factors for up to 14 days in cartilage and tendon lesions.
Indications
- Lesions that require a more stable and prolonged regenerative effect
Xerthra separation system
The Xerthra separation device delivers platelet concentrations up to 12 times higher than unprocessed blood.
- Autologous procedure
- No risk of immune response or disease transmission. Tissues are stimulated by the patient's own growth factors.
- Low blood volume
- Requires only 13.5 ml of blood for the procedure.
- Short centrifugation time
- A fast protocol that preserves sterility and safety.
- Makrolon polymer
- Very low surface energy and low affinity for platelets and leukocytes, ensuring maximum recovery of these factors at the end of the protocol.
- Guaranteed stabilization
- Transverse rings ensure stability during centrifugation, preventing hemolysis.
Technology
Xerthra tube technology
Closed system with pressure equalization
Blood transfer without removing the stopper, eliminating exposure and reducing contamination risk throughout the process.
Very low surface energy
A property of the Makrolon polycarbonate that minimizes platelet and leukocyte adhesion to the tube's inner wall, resulting in greater cell recovery in the final concentrate.
Transverse stabilization rings
Internal structures that keep the blood column stable during centrifugation, preventing hemolysis and preserving the integrity of the separated fractions.
Precision volumetric markings
Allow the exact volume to be obtained at each separation stage, with strict control over the final dose to be applied.
